Curriculum Vitae:
William Philip Werschler, MD, FAAD, FAACS
Office Address
324 South Sherman Street
Phone: (509) 624-1184
Building A1
Fax: (509) 625-1449
Spokane, WA 99202
Email: pkwerschle@aol.com
Education
1981 – 1985
MD, Graduation Honors
George Washington University Medical Center
Washington, DC
1976 – 1981
BA, BS, Magna Cum Laude
Eastern Washington University
Cheney, WA
Post Graduate Education
1997
Physician Entrepreneur Program
Kellogg Graduate School of Management
Northwestern University
Evanston, IL
1988 – 1989
Chief Resident, Dermatology
George Washington University Medical Center
Washington, DC
1986 – 1988
Resident, Dermatology
George Washington University Medical Center
Washington, DC
1985 – 1986
Internship, Internal Medicine
University of Arizona
Tucson, AZ
Academic Appointments
1992 – Present
Associate Clinical Professor in Medicine/Dermatology, University
of Washington
1989 – 1992
Clinical Instructor in Medicine/Dermatology, University of
Washington
1986 – 1989
Clinical Instructor
George Washington School of Medicine
Washington, DC
Professional Experience
2005 – Present
Clinical Research, Premier Clinical Research
Principal Investigator
324 South Sherman Street Building A2, Spokane, WA 99202
1992 – 2005
Clinical Research, Spokane Dermatology Clinic
324 South Sherman Street Building A2, Spokane, WA 99202
1989 – Present
Private Practice, Spokane Dermatology Clinic
324 South Sherman Street Building A1, Spokane, WA 99202
1987 – 1989
Consultant, HMO
George Washington University Health Plan Washington, DC
Certification
Diplomat, National Board of Medical Examiners
Board Certified, American Board of Dermatology
Fellow, American Academy of Dermatology
Fellow, American Academy of Cosmetic Surgery
Fellow, American Society for Dermatologic Surgery
Basic Life Support
Advanced Cardiac Life Support
Licensure
Washington, MD00026292
Hawaii, MD 13631
New York, 238324
Arizona, 34865
California, G87651
Nevada, 11969
Washington DC, MD036622
Idaho, M-9860
Colorado, 45897
Illinois, 036.121527
Michigan, 4301093194
Honors
2004
Model State Award presented to Washington State Dermatology Association
by American Academy of Dermatology Association, (Wm. Philip Werschler
President of Washington State Dermatology Association).
2002 – 2006
Best Doctors in America
2001
Alumnus Service Award, EWU Alumni Association
1985
Walter F. Rosenburg Award in Dermatology,
George Washington University Medical School
Graduation Honors
1985
Kane King Honor Society,
George Washington University Medical School
Graduation Award
1982 – 1993
Levine Foundation Scholarship
George Washington University Medical School
1981
Magna Cum Laude Graduation Honors
Eastern Washington University
1981
US Jaycees Outstanding Young Men of America Award
Organizational Leadership
1990 – 1992
Eastern Washington University College of Science, Math and
Technology Advisory Committee
1992 – Present
Leaders Society, Dermatology Foundation; State Chairman ’94-96
1993 – 1999
Eastern Washington University Foundation Board of Directors
1997 – 1999
Washington State Medical Association, Board of Trustees
1996
President, Spokane County Medical Society
1996 – 2000
Spokane Momentum Economic Development Council
1997 – 1998
United Way of Spokane County, Board of Directors
1995 – 1996
American Cancer Society, Spokane Chapter President
1992
Leadership Spokane Graduate
1993 – 1995
Leadership Spokane, Board of Directors
1998 – 2004
Dermatology Medical Director, Dermik Laboratories
2003
Lifetime Member, Annenberg Circle & Leaders Society, Dermatology
Foundation
2003 – 2004
President, American Society of Cosmetic Dermatology & Aesthetic Surgery
(ASCDAS)
2001 – Present
Board of Directors, ASCDAS
2004 – 2005
President, Washington State Dermatology Association
2005
Lifetime Founding Member, Amonette Circle, Skin Cancer Foundation
2005 – 2006
International Society on Cosmetic and Laser Surgery, Board of Trustees
2008 – 2009
President, American Society of Cosmetic Dermatology &
Aesthetic Surgery (ASCDAS)
Professional Organizations
Fellow, American Academy of Dermatology
Fellow, American Academy of Cosmetic Surgery
Fellow, American Society of Dermatologic Surgery
Fellow, American Society of Mohs Surgery
Fellow, Past President, American Society of Cosmetic Dermatology & Aesthetic Surgery
Fellow, International Society of Dermatology Surgery
Member, American Academy of Anti-Aging Medicine
Member, American Society of Laser Medicine and Surgery
Member, Washington State Medical Society
Member, Past President, Washington State Dermatology Association
Member, Past President, Spokane County Medical Society
Member (Past), Judicial Council, Washington State Medical Association
Clinical Research
Conducts the following studies with trained and experienced full-time in-office Clinical Research
Coordinators in association with Spokane Dermatology Clinic and Premier Clinical Research, LLC:

Dermik Laboratories: “A Pilot Multi-Center, Patient Preference Study Comparing Two
XXX/XXX Gels for treatment of Acne.” (2005-2006)

Graceway Pharmaceuticals “Open Label Safety and Pharmacokinetic Study of XXX for One,
Two, or Three Treatment Cycles to Surface Areas Greater than 25 square centimeters with
Actinic Keratosis. (2005-2007)

Allergan “A Double Blind Dose Comparison of the Safety and Efficacy of XXX in the
treatment of Female Subjects with Moderate or Severe Glabellar Rhytides. (2006)

Galderma: “A Multi-center, Randomized, double blind, Parallel-group Study to demonstrate
the Efficacy and Safety of XXX in Subjects with Acne Vulgaris”. (2006-Present)

Peplin “A multi-center, randomized, double-blind, double dummy, vehicle –controlled
sequential cohort study to determine the safety of XXX in patients with Actinic Keratoses”.
(2006-2007)

Allergan “Comparative Effectiveness and Safety of XXX vs. XXX in Lip Augmentation Pilot
Study”. (2007)

CollaGenex “A Multi-Center Randomized, Double-Blind, Active-Control Clinical Trial to
Determine the Effects of XXX in Patients with Moderate to Severe Rosacea. (2007)

Johnson & Johnson “The Pump Study” An Open Label, Community Based, Phase Four Study
to assess Facial Acne Improvement with the use of XXXX. (2007)

“A Multi-Center, Double-Masked, Parallel Study Assessing the Safety and Efficacy of OnceDaily Application of XXX Solution Compared to Vehicle in Increasing Overall Eyelash
Prominence”. (2007)

Allergan “A Multi-Center, Open Label Feasibility Study of the Safety and Effectiveness of XXX
Injectable Gel in Subjects Who Desire Lip Enhancement”. (2007-2008)

“A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the
Efficacy and Safety of XXX 0.1% Compared With Vehicle Lotion in Subjects with Acne
Vulgaris”. (2008-Present)

Artes Medical “Protocol for the Post-Approval Study of XXX for Correction of Nasolabial
Folds”. (2007-Present)

MS-1000, “Study of Cryo-Remodeling for Facial Enhancement”. (2007-Present)

XXX-PSOR-201 “A Phase II Study of the Dose-Effect of XXX Ointment in Patients with
Plaque-Type Psoriasis”. (2008-Present)

ARTES Medical “Protocol for the Post-approval Study of Artefill for Correction of Nasolabial
Folds. (2008)

Warner Chilcott “A Randomized Double Blind Study to Evaluate the Safety and Efficacy of
three Doses of a New Oral Formulation of XXXX as Compared to Placebo in the Treatment of
Moderate to Severe inflammatory Facial Acne Vulgaris. (2008)

STIEFEL: A Phase III Multicenter Randomized Double Blind Active and Vehicle Controlled
Study of the Safety and Efficacy of XXXX Gel Verses XXX Gel Verses XXXX Gel Verses Vehicle
in Subjects with Acne Vulgaris. (2008)

Actacis Mid-Atlantic LLC “A Multicenter Double Blind Randomized Parallel Group Vehicle
Controlled Study to Determine the Clinical Equivalence of Generic XXXX and XXXX Cream in
Subjects With Actinic Keratosis. (2008)

Abbot “A Phase III Multicenter Randomized Double Blind Placebo controlled Study
Comparing the Safety and Efficacy of Two Dosing Regimens XXXX to Placebo in Subjects
with Moderate to Severe Chronic Plaque Psoriasis. (2008)

Galderma “Open Label Randomized Split Face Study to Evaluate the Efficacy Safety and
Subject Satisfaction of pain Management During and After XXXX Dermal Filler Injections for
the Correction of Nasolabial Folds. (2008)

Taro, Inc. “A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site
Clinical Study to Evaluate the Bioequivalence of Two XXXX Topical Ointment Formulations
in Patients with Moderate to Severe Atopic Dermatitis”. (2008-2010)

Dow “A Phase 2B Multi-Center, Double-Blind, Randomized, Dose-Ranging Clinical Trial to
Evaluate XXXX in the Treatment of Moderate to Severe Acne Vulgaris with Nodular
Involvement”. (2008-2009)

A Placebo-Controlled, Double-Blind, 2-Dose-Level (50mg and 200mg TID) Study of a 28-Day
Treatment with XXXX Tablets in Adult Patients with Atopic Dermatitis. (2009-2010)

Nycomed, Inc.: “A Multi-Center, Double Blind, Randomized, Vehicle-Controlled, ParallelGroup Study Comparing XXXX to XXXX and Both Active Treatments to a Vehicle Control in
the Treatment of Atopic Dermatitis”. (2009-2010)

Basilea “Efficacy and Safety of XXXX in the Treatment of Severe Chronic Hand Eczema
Refractory to Topical Therapy.” (2008-2012)

Serentis “A Phase II, Randomized, Double-Blind, Vehicle Controlled, Cross-Over Study to
Determine the Anti-Pruritic Efficacy, Safety and Local Dermal Toleration of XXXX Cream in
Subjects with Atopic Dermatitis”. (2009-2010)

Galderma, “A Phase 4, Open-Label, Multi-Center, Community-based, 12-week Trial
Assessment of Effectiveness, Safety, and Subject Satisfaction with XXXX XXXX When Used as
Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of
Rosacea. (2009-2010)

Peplin, “A multi-center, Randomized, Parallel Group, Double-Blind, Vehicle-Controlled study
to evaluate the Efficacy and safety of XXXX In Patients with Actinic Keratoses on the head,
face or scalp. (Region-IIb) (2009-2010)

Myoscience, “Study of Cryo-Remodeling for Facial Enhancement: A Prospective, NonRandomized Study to Evaluate the Performance of the Myoscience Cryo-Remodeling Device
for the Treatment of Glabellar Lines (Frown Lines), Lateral Orbital Lines (Crow’s Feet),
Perioral Lines and Frontalis Lines (Horizontal Forehead Lines). (2008-2010)

Pacific Biosciences Laboratories, Inc.: A One Day Research Study Designed to Evaluate the
Immediate Effects of Your Fine Lines/Wrinkles Around Your Eyes When a Sonic Applicator
is Used to Apply a Serum to the Crow’s Feet and Under Eye Area. (2009-2010)

ISOCT.08.01 A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the
Efficacy and Safety of XXXX in Patients with Severe Recalcitrant Nodular Acne. (2010 2011)Protocol Number: RD.06.SPR.18161 A 4-Week, Randomized, Double-Blind, ParallelGroup, Vehicle- Controlled, Multicenter Study Investigating the Efficacy and Safety of XXXX
Applied Topically Once Daily (QD), and XXXX Topically Once Daily(QD) or Twice Daily
(BID), in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea. (20102011)
DPSI-IDP-108-P3-02 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating
the Safety and Efficacy of XXXX Topical Solution versus Vehicle in Subjects with Mild to
Moderate Onychomycosis of the Toenails. (2010-2011)
191622-099 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group
Study to Evaluate the Safety and Efficacy XXX Type A)Purified Neurotoxin Complex in
Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines). (2011- 2012)
BLI1100-202 A randomized, controlled evaluation of the safety and efficacy of topical
treatments for moderate-severe facial acne vulgaris. (2013-Present)
A Multi-Center Randomized, Double Blind parallel-Group Vehicle and Active Controlled
Study to Compare the Efficacy and Safety of XXXX Topical Gel Versus Topical Gel Vehicle in
Subjects with Acne Vulgaris. (2013-Present)
A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of XXXX and
Vehicle Gel in the treatment of Rosacea. (2011-2012)






Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of XXXX Versus
Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area. (2011Present)

A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of
Encapsulated XXXX and Vehicle Gel in the Treatment of Rosacea. (2011-2012)

Phase 3 Randomized Study of the Use of XXXX for Moderate to Severe Atrophic Facial Scar
Correction. (2012-Present)

A Phase 3b, Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate a
"Subject-Tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe
Plaque Psoriasis. (2012-Present)

A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly
XXXX with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy
(AWARD-8: Assessment of Weekly XXXX in Diabetes - 8). (2012-2013)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess
Cardiovascular Outcomes Following Treatment with XXXX in Subjects with Type2 Diabetes
Mellitus. (2012-Present)

A 64-week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the
Efficacy, Safety and Tolerability of Subcutaneous XXXX, Followed by an Optional Long Term
Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis.
(2012-Present)

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel-Group Clinical Trial
to Assess the Safety and Efficacy of XXXX Topically Applied Twice Daily for 12 Weeks in
Patients with Papulopustular Rosacea. (2012-Present)

Randomized Double-Blind Double-Dummy Placebo Controlled Study of the Safety and
Efficacy of XXXX and Immediate Release XXXX in the Treatment of Symptoms of Acute
Upper Respiratory Tract Infections for Seven Days. (2011-2012)

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens
of XXXX Compared with Placebo and XXXX in Subjects with Moderate to Severe Plaque
Psoriasis. (2011-Present)

LEO 80185-G23 XX plus XXX XXX Topical Suspension Compared to XXX XXX in the Topical
Suspension Vehicle, XXX in the Topical Suspension Vehicle and the Topical Suspension
Vehicle Alone in Psoriasis Vulgaris. (2012-2013)

A Multicenter Randomized Placebo-Controlled Double-Blind Parallel Study to Evaluate the
Efficacy and Safety of XXXX in Adult Subjects with Atopic Dermatitis. (2012-Present)

A Sequential Treatment Regimen of Cryotherapy and XXXX Field Therapy Compared to
Cryotherapy Alone for the Treatment of Actinic Keratosis. (2012-2013)

A Safety and Efficacy Study to compare Dapsone Dermal Gel with Vehicle Control in Patient
with Acne Vulgaris. (2013-Present)
Content Validity of Patient-Reported Outcome Items to Assess Aesthetic Improvement
Associated with Cellulite Treatment in a Patient Population with Cellulite. (2013-Present)
A 48 Week Study of Three Different Dose Regimens of BI 655066 Administered
Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis (Randomised,
Dose-Ranging, Active-Comparator-Controlled (Ustekinumab), Double-Blind within Dose
Groups of BI 655066. (2013-Present)



A Randomized, Double-Blind, Vehicle Controlled, Multicenter, Parallel Group Study of the
Safety of Betamethasone Dipropionate Spray 0.05% vs Dipropolene (Augmented
Betamethasone Dipropionate) Lotion 0.05% and the Efficacy of Betamethasone
Dipropionate Spray 0.05% vs Vehicle Spray in the Treatment of Moderate Plaque Psoriasis.
(2013-Present)

A Multicenter Double Blind Randomized Vehicle Controlled Dose Range Study of
Encapsulated Benzoyl Peroxide Gel 1% and 5% and Vehicle Gel in the Treatment of Rosacea.
(2013-Present)

Phase 3 Randomized Study of the Use of Artefill for Moderate to Severe Atrophic Facial Scar
Correction Evidera Cellulite Questionnaire Study. (2013-Present)

A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic
Exposure, and Pharmacodynamics of Calcipotriene foam 0.005%, Versus Vehicle Foam in
Pediatric Subjects (ages 2 to 11 Years) with Plaque Psoriasis. (2013-Present)

A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a
"Subject-tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe
Plaque Psoriasis. (2013-Present)

A Study Evaluating the Effect of Polylaser Dry Mask in Combination with the Polyhydrate
Mask as an Adjunctive Agent in Ablative or Fractional Ablative Laser Resurfacing. (2013Present)

A Study Evaluating the Effect of Polyhydrate Mask as an Adjunctive Agent in Cosmetic Facial
Procedures. (2013-Present)

A Study Evaluating the Effect of Polyhydrate Lip and Crows Feet Masks as Adjunctive Agents
in Cosmetic Facial Procedures. (2013)

A Study Evaluating the Effect of a Polyhydrate Mask as an Adjunctive Agent in
Microdermabrasion Treatment. (2013)

A Multicenter, Open-Label Study of the Long-Term Safety of AN2728 Topical Ointment, 2%
in the Treatment of Children and Adolescents (Ages 2-17 Years) With Atopic Dermatitis.
(Present)

A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens
of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to
Severe Plaque Psoriasis. (2013-Present)

A Phase 2 Randomized Double Blind Placebo Controlled Dose Ranging Study of Repeat
Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy. (2014)

A Phase 2 Randomized Double Blind Vehicle Controlled Dose Ranging Study of the Effect of
Drm04B in Subjects with Axillary Hyperhidrosis. (2013-Present)

Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three
Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm on
the Chest in Subjects with Actinic Keratosis. (2013-Present)

A Phase 3 Trial Comparing Once Daily Treatment with LEO 90100 Calcipotriol 50mcg/g
plus Betamethasone 0.5mg/g with Vehicle in Subjects with Psoriasis Vulgaris. (2013Present)

A Follow-up Evaluation of Study Subjects treated in Protocol ISOCT.08.01 - the Phase 3
Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy and Safety of
Cipisotretinoin in Patients with Severe Recalcitrant Nodular Acne. (2013-Present)

Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity
Using a Customized, High-Density and Vectoring Treatment Approach. (2013-Present)

Efficacy and Safety of Oxymetazoline HCI 1.0% for the Treatment of Persistent Erythema
Associated with Rosacea. (2014)

Content Validity of Patient-Reported Outcome Items to Assess Aesthetic Improvement
Associated with Cellulite Treatment in a Patient Population with Cellulite. (2014)

A Double-Blind, Randomized, Parallel-group, Active-Control Study to Compare the Efficacy
and Safety of CHS-0214 DP Versus Enbrel in Subjects with Chronic Plaque Psoriasis (CHS0214-04). (2014)

A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Four-Arm, Parallel
Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment,
in Subjects with Mild/Moderate Atopic Dermatitis. (2014)

A Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Phase II Dose-Ranging
Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients with Actinic Keratoses
(AK). (2014)
Editorial Boards
2008 – Present
SKINmed Journal: Dermatology for the Clinician, Editorial Board
2007 – Present
Journal of Clinical and Aesthetic Dermatology, Aesthetic Editor-in-Chief,
Matrix Medical Communications
2006 – Present
Cosmetic Dermatology, Editor-in-Chief, Quadrant Healthcom, Inc.
2006 – Present
Aesthetic Buyers Guide, Editorial Advisory Board, Medical Insight, Inc.
2006 – Present
Dermatology Times, Editorial Council, Advanstar Communications
2006 – Present
Medesthetics: Business Education for Medical Practitioners, Advisory
Board, Creative Age Publications.
2003 – Present
Journal of Drugs in Dermatology, International Editorial Board,
Strategic Communication in Dermatology, Inc.
2001 – Present
Cutis, Editorial Advisory Board, Quadrant Healthcom, Inc.
2001 – 2006
Cosmetic Dermatology, Senior Editor, Quadrant Healthcom, Inc.
2001 – 2004
Triple I Podiatry Prescribing Guide, Editorial Advisory Board,
MediMedia USA, Inc.
2001 – 2004
Pathways to Clinical Practice, Editor, Quarterly Newsletter,
HMP Publications, Inc.
1999 – 2012
Skin & Aging, Editorial Advisory Board, Contributing Editor,
HMP Communications, Inc
1997 – 1999
Progressive Clinical Insights, Editorial Board, Contributing Editor,
Paramedical Consultants, Inc.
Publications

Werschler, WP, Elgart, ML, Williams, CM. Progressive asymptomatic annular facial skin
lesions. Cutaneous tuberculosis. Archives of Dermatology. September 1990. Vol 126 (9):
1227, 1229-1230.

Werschler, WP. Total Intravenous Anesthesia for Office-Based Laser Facial Resurfacing.
Lasers in Surgery and Medicine; Supplemental 9, 1997:34.

Werschler, WP, et al. Cosmetic Office Practice – A Novel Perspective. Progressive Clinical
Insights, January/February 1998; Vol. 6(1): 24-25.

Werschler, WP. Why the Time is Now to Promote Cosmetic Procedures. Skin & Aging, April
1998; Vol. 6(4): 32-33.

Werschler, WP. How You Can Integrate Cosmetic Procedures Into Your Practice. Skin &
Aging, May 1998; Vol. 6(5): 41-43.

Werschler, WP. Overcome the Challenges of Adding Laser Procedures to Your Practice.
Skin & Aging, July 1998; Vol. 6(7): 59-62.

Trytko R, Werschler, WP. Total Intravenous Anesthesia for Office-Based Laser Facial
Resurfacing. Lasers in Surgery and Medicine; Supplemental Vol 25(2), 126-130, 1999.

Werschler, WP. Making Mid-level Providers Work for You. Skin & Aging, February 1999;
Vol. 7(2): 53-57.

Werschler, WP., et al. Emollients: Current Uses and Future Trends. Skin & Aging, June 1999
Supp.; Vol. 7(6).

Werschler, WP. What to Do When the HMO Says “No!” Skin & Aging, August 1999; Vol. 7(8):
46-49.

Werschler, WP. The Promise and Pitfalls of Private Practice. Skin & Aging, January 2000
Supp.; Vol. 8(1): 4-7.

Werschler, WP. Wake Up Your Practice with These 13 Tips. Skin & Aging, February 2000;
Vol. 8(2): 58-62.

Werschler, WP. How to Introduce Liposuction into Your Practice. Skin & Aging, April 2000;
Vol. 8(4): 39-45.

Werschler, WP., et al. Rethinking Onychomycosis. Skin & Aging, July 2000 Supp.; Vol. 8(7).

Werschler, WP. Botox: Inject New Life Into Your Practice. Skin & Aging, August 2000
Supp.; Vol 8(8)

Parish, LC, Routh, HB, Miskin, B, Fidelholz, J, Werschler, P, Heyd, A, Haverstock, D, Church,
D,. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.
International Journal of Clinical Practice. October 2000; Vol 54(8):497-503.

Werschler, WP. Eczema and Contact Dermatitis. American Journal of Medicine and Sports,
2000; Vol. 2(3): 178-181, 202.

Werschler, WP with Craze, MG. How to Develop, Manage & Market a Cosmetic Practice, Text
Book. PPMS, Spokane, WA.

Werschler, WP, Bondar, GL, Smith, SS. Occupational Risks of Malignant Melanoma. Clinics
in Occupational and Environmental Medicine, February 2001: 75-84.

Werschler, WP. What You Need to Know About the Fickleness of Cash Flow. Skin & Aging,
April 2001; Vol. 9(4): 27-28.

Werschler, WP. Economic Forecasting For Practice Development. Skin & Aging, May 2001;
Vol. 9(5): 21-22.

Werschler, WP. Advice for Dispensing Prescription Pharmaceuticals. Skin & Aging, June
2001; Vol. 9(6): 22-24.

Werschler, WP. How to Identify Problems with Your Practice. Skin & Aging, September
2001; Vol. 9(9): 91-93.

Werschler, WP., Baumann, Leslie. Everything You Need To Know About Botox Injection.
Skin & Aging, October 2001; Vol 9(10): 36-42.

Werschler, WP. Mechanism of Drug Action Important to Consider. Dermatology Times,
November 2001; Vol. 22 Supp. 5: S8-S9.

Werschler, WP., et. al. (BOTOX Glabellar Lines I Study Group). “A multicenter, double-blind,
randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in
the treatment of glabellar lines” Journal of American Academy of Dermatology, 2002;
46:840-9.

Werschler, WP., et al. Introducing a New Service in the Dermatology Practice. Skin & Aging,
January 2002; Vol. 10(1): 43-47.

Werschler, WP., et al. Treatment of Onychomycosis in the Elderly. Clinical Geriatrics, April
2002; Vol 10(4): 19-29.

Werschler, WP. Mixed Infection and Urticarial Drug Reaction Following CO2 Laser/TCA
Peel. Cosmetic Dermatology, August 2002; Vol. 15(8): 21-22.

Werschler, WP. 10 Questions to Ask if You are Thinking About Receiving Botox Cosmetic
Therapy. Healthy Skin & Hair Summer, 2002:7.

Werschler, WP. A New Era of Actinic Keratosis Treatment. Skin & Aging, September 2002;
Vol 10 Supplement 9: 1-15.

Werschler, WP., et. al (Roundtable Participants). Clinical Dialogues: Actinic Keratosis and
Other Nonmelanoma Skin Cancers. A Supplement to Skin & Allergy News, 2004.

Werschler, WP., et. al. Assessing Treatment Outcomes in Toenail Onychomycosis Clinical
Trials. American Journal of Clinical Dermatology, 2004; 5 (3): 145-152.

Gupta, AK, Carney, PS, Jegasothy, SM, Turner, JE, and Werschler, WP, Onychomycosis:
Management and Treatment. July 2004; Vol 74 (1S) 16-24.

Werschler, WP, Hanke, W, and Weinkle, S, The Aging Face: More Than Skin Deep, July 2004.

Carruthers, Jean, M.D., Fagien, Steven, M.D., Matarasso, Seth L., M.D., Werschler, WP., et. al.
(the Botox Consensus Group). Introduction to the Consensus Recommendations.
Supplement to Plastic and Reconstructive Surgery, November 2004; Vol 114(6): i-22S.

Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Fluorouracil 5% and
0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower
concentration and more convenient dosing schedule. Cutis, December, 2004; Vol 74 (6
Suppl): 18-23.

Jorizzo, Joseph L., M.D., Carney, Patrick S., M.D., Ko, William T., M.D., Robins, Perry, M.D.,
Weinkle, Susan H., M.D., and Werschler, WP (Rountable Participants). Which options when:
How to Maximize the Treatment Outcomes for Actinic Keratosis. Supplement to Cutis,
December 2004; Vol 74(6S): 4-25.Review.

Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Treatment Options in
the management of actinic keratosis. Cutis. December 2004. Vol 74(6 Suppl):9-17. Review.

Jorizzo, JL, Carney, PS, Ko, WT, Robins, P, Weinkle, SH, Werschler, WP. Matching patients
with therapy. Cutis. December 2004. Vol 74 (6 Suppl): 5-8. Review.

Werschler, WP, Bondar, GL, and Esch, PJ, 6 Simple Steps to Sculptra Success. Skin & Aging,
January 2005; Vol 13(1): 56-59.

Werschler, WP, and Weinkle, Susan, M.D.. Longevity of Effects of Injectable Products for
Soft Tissue Augmentation. Drugs in Dermatology, January 2005: New Methods and
Techniques; Vol 4(1): 20-27.

Werschler, WP. Advances in Recognizing and Treating Facial Lipatrophy. A Supplement to
Cosmetic Dermatology, February 2005; Vol 18(2 S2): 1-4.

Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Monitoring the Financial Health of
Your Practice. Skin & Aging, February 2005; Vol 13(2):18-19.

Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Should You Use a Cost-Sharing
Agreement? Skin & Aging, March 2005; Vol 13(3): 31-32.

Werschler, WP and Mest, Douglas R., MD. Questions and Answers: ASCDAS 3rd Annual
Meeting – New Options in the Recognition and Treatment of Lipoatrophy with Volume
Restoration. Cosmetic Dermatology, March 2005; Vol 18(3): 235-239.

Werschler, WP (Moderator), Berson, Diane S., MD, Weinkle, Susan H., MD, Weiss, Jonathan
S., and Woodson, Johnnie M., MD. The Expanding Role of 5-FU in Dermatology. Supplement
to Dermatology Times, April 2005.

Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Avoid Employee Theft:
Implement Internal Controls. Skin & Aging, May 2005; Vol 13(5): 33-34.

Werschler, WP and Vleggaar, Danny, MD. Fillers to Sculptors: Addressing Volumentric
Restoration / New Treatment Options in Lipoatrophy. Supplement to Dermatology Times,
August 2005.

Werschler, WP, Larson, Kari, BBA, and Hardland, Brad, CPA. Practice Pearls: Choosing the
Right Paid-Leave Policy. Skin & Aging, September 2005; Vol 13(9); 37-40.

Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Establishing and Evaluating
Patient Satisfaction with your Practice. Cosmetic Dermatology, October 2005; Vol 18 (10);
699-701.

Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Practice Pearls: Should you
Start your own Practice or Join an Existing One? Skin & Aging, October 2005; Vol 13 (10);
33-36.

Werschler, WP. Achievements in Cosmetic Dermatology Recognized at ASCDAS Meeting,
Guest Editorial. Cosmetic Dermatology, January 2006; Vol 19 (1); 21.

Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Promoting the Growth of Your
Cosmetic Practice. Cosmetic Dermatology, January 2006; Vol 19 (1); 31-34.

Werschler, WP, Rendon, Marta, MD, and Ditre, Cherie, MD. Facial Volume Restoration:
Selecting and Applying Appropriate Treatments. Cosmetic Dermatology Supplement,
February 2006; Vol 19 (2 S1); 1-12.

Werschler, WP, et.al. Atopic Dermatitis: Emerging Therapies. Supplement to Skin & Aging,
February, 2006.

Werschler, WP, Eichenfield, LF, Chamlin, SL, Friedlander, SF. Recent Advances in the
Management of Atopic Dermatitis. Supplement based on a faculty clinical roundtable
discussion, affiliation with Skin Disease Education Foundation’s 30th annual Hawaii
Dermatology Seminar, February 2006.

Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. The Growing Role of Physician
Extenders, Part 1. Skin & Aging, March 2006; Vol 14 (3); 29-31.

Werschler, WP, et. al. Don’t Leave the Wrong Impression on Your Cosmetic Patient.
Cosmetic Dermatology, April 2006; Vol 19 (4); 275-276.

Werschler, Larson, Kari, BBA, and Harland, Brad, CPA. Using Physician Extenders, Part 2.
Skin & Aging, May 2006; Vol 14 (5); 30-32.

Werschler, WP, Cohen, JL, and Hirsch, RJ. ASCDAS 4th Annual Meeting Q&A’s, Cosmetic
Dermatology May 2006 Vol 19 (5); 337-338.

Maley, Catherine, MBA, Werschler, WP, and Larson, Kari, MBA. Thinking About Adding a
Laser to Your Practice? Renting Versus Owning. Cosmetic Dermatology, June 2006; Vol 19
(6); 400-402.

Werschler, WP, Radiesse and Other Soft Tissue Fillers. Aesthetic Trends & Technologies,
Summer 2006; Vol 5 (4)

Werschler, WP, Berg, Roy, Larson, Kari. “Medical Equipment: Buy or Lease?” Skin & Aging,
July 2006; 38-40.

Werschler, WP, Larson, Kari, Harland, Brad. “Promoting the Growth of Your Cosmetic
Practice”. Volume 14 (3); 6.

Werschler, WP. “Vivelif Offers New Technology for Wrinkles”. Aesthetic Buyers Guide,
September/October 2006; 3.

Werschler, WP. “U.S. Fillers Market Set to Boom” Cosmetic Surgery Time, October 2006.
Vol.9 (9); 12-14.

Werschler, WP, Fried, R. Cover Article “The Key to Mastering Cosmetic Dermatology Patient
Selection”. Skin & Aging, October, 2006; Vol 14(10): 42-50.

Werschler, WP. “Fillers, Toxins, Lasers, and More at the Annual ASCDAS Meeting”. Cosmetic
Dermatology, November 2006; Vol 19(11): 668

Werschler, WP; Smith, Scott, DO. “Mechanism of Action of Poly-L-Lactic Acid: A Stimulatory
Dermal Filler”. Supplement to Journal of Drugs in Dermatology, January 2007: Vol 6(1):1820

Werschler, WP. “Hitting the Cosmetic Dermatology Jackpot”. Cosmetic Dermatology.
January 2007; Vol 20(1) Editorial 14

Fagien, Steven, MD, FACS; Cox, Sue Ellen, MD; Finn, Charles, MD; Werschler, WP, Kowalski,
Jonathan, PharmD, MS. “Patient-Reported Outcomes with Botulinum Toxin Type A
Treatment of Glabellar Rhytids: A Double-Blind, Randomized, Placebo-Controlled Study”.
Dermatologic Surgery, January 2007; Vol 33(1): S2-S9 ISSN 1076-0512

Werschler, WP. “Combining Advanced Injection Techniques: Poly-L-Lactic Acid as the
Foundation for Nonsurgical Total Facial Rejuvenation and Restoration”. A supplement to
Cosmetic Dermatology, February 2007; Vol 20(2 S1): 9-13

Tanghetti E, Werschler WP. Comparison of 5% 5-fluorouracil cream and 5% imiquimod
cream in the management of actinic keratosis on the face and scalp. Journal of Drugs in
Dermatology, Feb 2007; 6(2): 144-7.

Rendon, Marta I., MD; Sengelmann, Roberta D., MD; Weinkle, Susan, MD; and Werschler, WP.
“Recognition and Treatment of Facial Lipoatrophy with Volume Restoration”. Medscape.
March 2006

Werschler, WP. “Advanced Injection techniques of poly-L lactic acid: a case-based
presentation”. Guest Editor in Dermatologic Therapy, March 2007; Vol 20, Suppl. 1

Werschler, WP. “Optimal Use of Facial Filling Agents: Understanding the Products”.
Cosmetic Dermatology, May 2007; Vol 20(5) Suppl. 2: 4-7

Werschler, WP. Details: “Modern Skin Preparation”. Medesthetics, September/October
2007: 12-14, 94.

Rosen, Ted, MD; Gold, Michael, MD; Werschler, WP. “Chemoprevention; Its Role In
Dermatology Treatments”. Skin & Aging, October Supplement: 15-22

Lupo, Mary, MD; Draelos, Zoe, MD; Farris, Patricia, MD; Mandy, Stephan, MD; McDaniel,
David, MD; Taylor, Susan, MD; Werschler, WP. “CoffeeBerry: A New, Natural Antioxidant in
Professional Anti-Aging Skin Care”. Cosmetic Dermatology, October 2007; Vol 20(10) Sup. 4

Larson-McMurtrey, Kari, MBA; Werschler, WP. “The Ins and Outs of a Practice Buy-in or
Buy-out”. Cosmetic Dermatology, October 2007; Vol 20(10): 626-629

Werschler, WP. “Fillers, Toxins, Lasers, and More at the Annual ASCDAS meeting”. Cosmetic
Dermatology, November 2006; Vol 19(11): Editorial

Buford, Gregory A., MD, Burgess, Cheryl M., MD, Lacombe, Victor G., MD, Sherman, Richard
N., MD, Vleggaar, Danny, MD, Weinkle, Susan H., MD, Werschler, WP. “The Role of
Stimulatory Fillers in Aesthetic Facial Rejuvenation”. Cosmetic Dermatology, November
2007; Vol 20(11) Suppl. 5

Werschler, WP. “Everyone is a Winner at ASCDAS”. Cosmetic Dermatology, November
2007; Editorial Vol 20(11): 696

Werschler, WP. “Treating the Aging Face: A Multidisciplinary Approach with Calcium
Hydroxylapatite and Other Fillers, Part 1”. Cosmetic Dermatology, November 2007; Vol
20(11): 739-742

Werschler, WP. “A Skin Cancer Cure?”. Family Circle, June 2008; 137

Del Rosso, James Q., MD, Schlessinger, Joel, MD, Werschler, WP. “Comparison of AntiInflammatory Dose Doxycycline versus Doxycycline 100 MG in the Treatment of Rosacea”.
Journal of Drugs in Dermatology New Methods and Techniques, June 2008; Vol 7(6): 573-6

Werschler, WP. “The Costs of Products and Services”. Cosmetic Dermatology, July 2008; Vol
21(7): 376-79

Werschler, WP. “What is in a Name?”. Cosmetic Dermatology, September 2008; Vol 21(9):
480-81Sadick NS, Anderson D, Werschler WP. “Addressing volume loss in hand
rejuvenation: a report of clinical experience”. Journal of Cosmetic Laser Therapy.
December 2008; Vol 10(4): 237-41

Del Rosso JQ, Schlessinger J, Werschler P. “Comparison of anti-inflammatory dose
doxycycline versus doxycycline 100mg in the treatment of rosacea”. Journal of Drugs in
Dermatology. December 2008; Vol 7(12): 573-576

Werschler, WP. “Appreciation and Compassion in Times of Economic Turmoil” Cosmetic
Dermatology, December 2008; Editorial Vol 21(12): 634-635

Werschler, WP. “Meeting Here, Meeting There, Meeting Everywhere?” Cosmetic
Dermatology, March 2009; Editorial Vol 22(3):116-117

Werschler, WP. “New Developments in Topical Anesthetics” The Journal of Clinical
Aesthetic Dermatology, April 2009; Vol 2(4): Suppl 23-25

Hema Sundaram, MD, Rahul C. Mehta, PhD, Josie A. Norine, MA, Leon Kircik, MD, Fran E.
Cook-Bolden, MD, Deborah H. Atkin, MD, W. Philip Werschler, MD, Richard E. Fitzpatrick,
MD. “Topically Applied Physiologically Balanced Growh Factors: A New Paradigm of Skin
Rejuvenation”. Journal of Drugs in Dermatology, May 2009; Vol 8(5) Supplement.

Lawrence Anderson, George J. Schmieder, W. Philip Werschler, Eduardo H. Tschen, et al.
“Randomized, double-blind, double-dummy, vehicle controlled study of ingenol mebutate
gel 0.25% and 0.05% for actinic keratosis.” Journal of the American Academy of
Dermatology, June 2009; Vol 60(6): 934-943

Werschler, WP. Advances in the Use of Toxins and Fillers Presented at Maui Derm ’09,
Guest Editorial. The Dermatology Report, Spring 2009; Vol 3 (1):37

Werschler, WP. “Hand Rejuvenation” MedEsthetics, Sept/Oct 2009; Vol 5(5):10-12

Werschler, WP. “United We Stand: Combined Annual Meeting of ASDS and
ASCDAS”Cosmetic Dermatology, October 2009; Editorial Vol 22(10): 499-500

Richard G. Fried, MD, PHD; WM Philip Werschler, MD; Tracy Floirendo, MA. ”The Botulinum
Toxin Experience – Results of a Patient Self-Report Questionnaire” The Journal of Clinical
and Aesthetic Dermatology, November 2009; Vol 2(11):37-40

James Q. Del Rosso, DO; Wm Philip Werschler, MD. “November Highlights” The Journal of
Clinical and Aesthetic Dermatology, November 2009; Vol 2(11):6

Werschler, WP; Busso, M. Prepackaged Injectable Soft-tissue Rejuvenation of the Hand and
Other Nonfacial Areas. In: Alam M and Pongprutthipan M, eds. Body Rejuvenation (Part 7).
New York: Springer, 2010; 30:221-225.

Rhonda S. Narins, MD, PC; Steven R. Cohen, MD, FACS. Wm Philip Werschler, MD. The FiveYear Investigator Study Group Contributor. “Novel Polymethylmethacrylate Soft Tissue
Filler for the Correction of Nasolabial Folds: Interim Results of a 5-Year Long-Term Safety
and Patient Satisfaction Study”. Dermatology Surgery 2010; 36:766-774.

Werschler, WP. et. al. “A randomized study of the efficacy and safety of injectable poly-Llactic acid versus human-based collagen implant in the treatment of nasolabial fold
wrinkles.” Journal of the American Academy of Dermatology, March 2010; Vol 62(3):448462.

Werschler, WP. “Thoughts on Acne and Rosacea”, Guest Editorial. Cosmetic Dermatology,
April 2010; Vol 23 (4):154

Werschler, WP. “The Summer Meeting of the American Academy of Dermatology: Chicago”,
Guest Editorial. Cosmetic Dermatology, July 2010; Vol 23(7):299-300

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Introduction”, Aesthetic Surgery Journal July/August
2010; 30:1 Suppl: 9S-10S.

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Nonsurgical Modalities to Treat the Aging Face”,
Aesthetic Surgery Journal July/August 2010; 30:1 Suppl: 31S-35S

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Update on Facial Aging”, Aesthetic Surgery Journal
July/August 2010; 30:1 Suppl: 11S-24S

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Facial Aesthetic Analysis”, Aesthetic Surgery Journal
July/August 2010; 30:1 Suppl: 25S-27S.

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Surgical Versus Nonsurgical Rejuvenation”, Aesthetic
Surgery Journal July/August 2010; 30:1 Suppl: 28S-30S.

Werschler, WP; Fitzgerald, Rebecca; Graivier, Miles H.; Kane, Michael; Lorenc Paul Z.;
Vleggaar, Danny; Kenkel, Jeffrey M. “Appropriate Selection and Application of Nonsurgical
Facial Rejuvenation Agents and Procedures: Panel Consensus Recommendations”, Aesthetic
Surgery Journal July/August 2010; 30:1 Suppl: 36S-45S.

Wm. Philip Werschler, MD; Nathan S. Trookman, MD; Ronald L. Rizer, PhD; Elizabeth T. Ho,
BS; and Rahul Mehta PhD. “Enhanced Efficacy of a Facial Hydrating Serum in Subjects with
Normal or Self-Perceived Dry Skin.” The Journal of Clinical and Aesthetic Dermatology,
February 2011; Vol 4 (2):51-55

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses non-melanoma skin cancer,
oral antibiotics, and efficacy of facial hydrating serum added to moisturizer regimen.
Journal of Clinical & Aesthetic Dermatology. Feb 2011, Vol 4(2):10

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published
within the issue. Journal of Clinical & Aesthetic Dermatology. March 2011, Vol. 4(3):8

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses reports published within
the issue. Journal of Clinical & Aesthetic Dermatology. April 2011, Vol. 4(4):12

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses reports published within
the issue which include the efficacy of benzoyl peroxide gel in treating proionibacterium
acnes, the factors that affect the optimal treatment of the seborrheic dermatitis, and medical
lasers. Journal of Clinical & Aesthetic Dermatology. May 2011, Vol. 4(5):10

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published
within the issue that include the study on the performance of dermatologist in self-skin and
full-body skin examinations, the prevalence on cosmetic allergens by the American Contact
Alternatives Group, and a case study on the treatment of patients with skin depigmentations
using excimer lasers. Journal of Clinical & Aesthetic Dermatology. June 2011, Vol. 4(6):12

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports with the
issue on topics including the effect of body image disturbance on the quality of life of acne
vulgaris patients. Journal of Clinical & Aesthetic Dermatology. July 2011, Vol. 4(7):12

Brandt FS, Cazzaniga A, Baumann L, Fagien S, Glazer S, Kenkel JM, Lowe NJ, Monheit GD,
Narins RS, Rendon MI, Rohrich RJ, Werschler, WP. “Investigator global evaluations of
efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial
fold wrinkles.” Aesthetic Surgery Journal, July 2011; 31(5)521-28

Wm. Philip Werschler, MD: “Mirror, Mirror on the Wall, Is My Injector the Best of All?”,
Guest Editorial. Cosmetic Dermatology, July 2011; Vol 24(7):304-305

Jo Lynne Herzog MD, James A. Solomon MD PhD, Zoe Draelos MD, Alan Fleischer Jr. MD,

“Investigator Global Evaluations of Efficacy of Injectable Poly-L-Lactic Acid Versus Human
Collagen in the Correction of Nasolabial Fold Wrinkles”. William Philip Werschler, MD &
others. Aesthetic Surgery Journal, Volume 31, Number 5, July 2011.

“Further Enhancement of Facial Appearance with a Hydroquinone Skin Care System Plus
Tretinoin in Patients previously Treated with Botulinum Toxin Type A”. Philip Werschler,
MD, FAAD, & others. Aesthetic Surgery Journal, Volume 31, Number 5, July 2011.

Dow Stough MD, David I.Wolf MD, William Abramovits MD, William Werschler MD, Emma
Green BSc, Maeve Duffy PhD, Alan Rothaul PhD, Robert Tansley MBBS. ”A Randomized,
Double-Blind, Vehicle-Controlled Crossover Study to Determine the Anti-Pruritic Efficacy,
Safety and Local Dermal Tolerability of a Topical Formulation (SRD174 Cream) of the LongActing Opiod Antagonist Nalmefene in Subjects With Atopic Dermatitis.” Journal of Drugs
Dermatology. 2011 Vol.10(8):853-860

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports published
within the issue including physical modalities for acne. Journal of Clinical & Aesthetic
Dermatology. Nov 2011, Vol. 4(11):8

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including treatment of cutaneous infections, efficacy of physiological lipid-based
topical emulsion and anatomic basis for malar edema. Journal of Clinical & Aesthetic
Dermatology. Dec 2011, Vol. 4(12):8

Werschler, WP.; Yates, Choo. “Experts Recognize Radiesse as a True Volumizing Dermal
Filler”. The Asian Aesthetic Guide. 2012, Vol.3:2

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including the effects of sinecatechins on proteases, the photostability of a
micronized formulation of tretinoin. Journal of Clinical & Aesthetic Dermatology. Jan 2012,
Vol. 5(1):10

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including treatment of plaque psoriasis with calcitrol ointment. Journal of Clinical
& Aesthetic Dermatology. Feb 2012, Vol. 5(2):1-10

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including managing rosacea, common clinical features of rosacea and persistent
facial erythema of rosacea. Journal of Clinical & Aesthetic Dermatology. Mar 2012, Vol.
5(3):9

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including the incidence of nonmelanoma skin cancer and actinic keratosis,
prognostic significance of follicular extension in AK, and effect of antioxidant combination in
women with photoaging. Journal of Clinical & Aesthetic Dermatology. Mar 2012, Vol.
5(4):10

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses various reports in the issue
on topics including the tolerability of clindamycin/benzoyl peroxide gel virus, the efficacy of
bluelight device in treating acne. Journal of Clinical & Aesthetic Dermatology. May 2012,
Vol. 5(5):9

Del Rosso, James Q.; Werschler, Wm. Philip. Abstract: Discusses pre-treatment with forced
heated air and treatment of vascular and pigmented lesions. Journal of Clinical & Aesthetic
Dermatology. June 2012, Vol. 5(6):10

Wm. Philip Werschler, MD: “Celebrating 25 Years”, Guest Editorial. Cosmetic Dermatology,
July 2012; Vol 25(7):297

Wm. Philip Werschler “Oral lesions associated with injected hydroxyapatite cosmetic filler”
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Volume 115, Issue 3, March
2013, Pages 417-419

James J. Leyden MD, Suzanne Bruce MD, Chai Sue Lee MD, Mark Ling MD PhD, Pranav B.
Sheth MD, Daniel M. Stewart DO, William P. Werschler MD, Richard D. Gilbert PhD, and Leon
Kircik MD. “A Randomized, Phase 2, Dose-Ranging Study in the Treatment of Moderate to
Severe Inflammatory Facial Acne Vulgaris with Doxycycline Calcium.” Journal of Drugs
Dermatology. June 2013 Vol. 12(6):658-663

Werschler, W. P. (2013). "Who is the aesthetic consumer?" Cutis Suppl: 5.

Z. Paul Lorenc, Suzanne Bruce, William Philip Werschler. “Safety and Efficacy of a
Continuous-Flow, Injection-Assisted Device in Delivery of Dermal Fillers.” Aesthetic Surgery
Journal. July 2013 Vol.33(5):705-712 Karnik, J., L. Baumann, S. Bruce, V. Callender, S.
Cohen, P. Grimes, J. Joseph, A. Shamban, J. Spencer, R. Tedaldi, W. P. Werschler and S. R.
Smith (2014). "A double-blind, randomized, multicenter, controlled trial of suspended
polymethylmethacrylate microspheres for the correction of atrophic facial acne scars." J Am
Acad Dermatol 71(1): 77-83.

Berman, B., G. Goldenberg, C. W. Hanke, S. K. Tyring, W. P. Werschler, K. M. Knudsen, J.
Goncalves, T. Larsson, T. Skov and N. Swanson (2014). "Efficacy and safety of ingenol
mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results." J
Drugs Dermatol 13(2): 154-160.

Berman, B., G. Goldenberg, C. W. Hanke, S. K. Tyring, W. P. Werschler, K. M. Knudsen, T.
Larsson and N. Swanson (2014). "Efficacy and safety of ingenol mebutate 0.015% gel after
cryosurgery of actinic keratosis: 12-month results." J Drugs Dermatol 13(6): 741-747.

“Development and Validation of a Photographic Scale for Assessment of Lip Fullness”, W.
Philip Werschler, & others, Aesthetic Surgery Journal, 2015, 35 (3): 294-307, doi:
10.1093/asj/sju025

“Superior Efficacy of the Fixed Combination Calcipotriene Plus Betamethasone
Dipropionate in an Innovative Aerosol Foam Versus Ointment, in Patients With Psoriasis
Vulgaris”, Authors: William Philip Werschler & others, Clinical Poster Highlights – a
supplement to Dermatology News, Volume 46, No. 4, April 2015
Electronic Media

Tina Alster, MD; Joseph Jorizzo, MD; Faculty: C. William Hanke, MD, MPH, FACP; Susan
Weinkle, MD; Wm. Philip Werschler, MD, FAAD. CME "The Aging Face: More than Skin Deep.
Release Date September 2004

Werschler, WP and Anderson, Richard, MD. Botulinum Toxin Type A and Facial
Enhancement – A practical Guide to Optimal Outcomes: An interactive, case study-based
CD-ROM presenting injection training from the Consensus Recommendations on the Use of
Botulinum Toxin Type A in Facial Aesthetics. Jointly sponsored by Postgraduate Institute
for Medicine and Health Learning Systems. Supported by an educational grant from
Allergan, Inc. Release Date August 2005.

Wm. Philip Werschler, MD, FAAD; Marta I. Rendon, MD, FAAD; Roberta D. Sengelmann, MD;
Susan Weinkle, MD, FAAD. Recognition and Treatment of Facial Lipoatrophy with Volume
Restoration. Supported by an independent educational grant from Dermik Aesthetics.
Release Date March 2006.

Werschler, WP, Chairman, Rendon, Marta, MD, Ditre, Cherie, MD. Facial Volume
Restoration: Selecting and Applying Appropriate Treatments. Jointly sponsored by
Postraguate Institute for Medicine and EHC Communications. Supported by an educational
grant from Dermik Aesthetics. Release Date April 2006.

Werschler, WP, Monheit, Gary, MD, Donofrio, Lisa, MD. Facial Lipoatrophy and Photoaging
Skin. MedsiteCME.com. Sponsored by Discovery Institute of Medical Education. Supported
by Dermik Aesthetics. Live Date June 16, 2006.

Werschler, WP, Chairman, Kinney, Brian, MD, Weinkle, Susan, MD, Lacombe, Victor, MD.
Facial Restoration: Advances in Non-Surgical Treatment Options for Volume Loss. Jointly
sponsored by Postraguate Institute for Medicine and EHC Communications. Supported by
an educational grant from Dermik Aesthetics. Release Date August 2006.

Braun, Martin, MD; Weinkle, Susan, MD; Werschler, WP. Mastering the Art of Soft Tissue
Fillers”. Provided through an Educational Grant from Dermik. Orlando Dermatology &
Aesthetic Conference. Orlando, Florida, 2006

Jones, Derek H., M.D., Werschler, WP. Full Facial Rejuvenation: Portraits in Patient
Satisfaction. An interactive CD-ROM presenting injection procedures. Jointly sponsored by
the Elsevier Office of Continuing Medical Education and Skin Disease Education Foundation.
Supported by an educational grant from Allergan, Inc. Release Date August, 2007.

Werschler, WP. Emerging Uses of Semi-Permanent Fillers. An Educational DVD joint
sponsorship of USF Health and i.e. aesthetics. Supported by an Educational Grant from
BioForm Medical. Release Date: December 2008

Mest, Douglas, MD; Werschler, WP. Profiles in Facial Rejuvenation: The Science and Art of
Biostimulatory Fillers. An Interactive CD-ROM. Jointly sponsored by the Elsevier Office of
Continuing Medical Education and Skin Disease Education Foundation. Supported by an
educational grant from Dermik, a business unit of Sanofi-Aventis U.S. Release Date: June
2009

Werschler, WP., July 7, 2014, Electronic brachytherapy allows collaboration between
dermatologists, radiation oncologists. Dermatology Times.

Werschler, WP., Beer, K., July 29, 2014, Verisante Technology, Inc. Welcomes Dr. Kenneth
Beer and Dr. Philip Werschler onto Clinical Advisory Board. Wall Street Journal.

Finance.yahoo.com. “Leading Aesthetic Physicans Join Neothetics’ Newly Formed Corporate
Advisory Board”. February 12th, 2015 8:00AM

Bellafill. “A Scar Free Me” Ask the Expert Post, Upkeep Treatment for Dermal Fillers, Dr.
Philip Werschler, March 30, 2015
Poster Presentations

Werschler, WP., et. al. Patient-reported outcomes in subjects receiving botulinum toxin type
A treatment for moderate to severe glabellar rhytides. 2006 AAD.

Werschler, WP, and Tanghetti, E. Efficacy and tolerability of 5% 5-Fluorouracil cream and
5% Imiquimod cream in the management of actinic keratoses on the face and scalp. 2006
AAD.

Werschler, WP. Evaluation of the safety and efficacy of a new superficial chemical peel.
2006 AAD.

Carruthers, A., MD; Carruthers, J., MD; Cox, S.E., MD; Fagien, S., MD; Finn, J.C., MD; Kowalski,
J., PharmD, MS; Lowe, N., MD; Ravelo, A. MPH; Stotland, M., MD; Werschler, W.P., MD.
Patients’ Self-Perception of Age after Botulinum Toxin Type A Treatment of Upper Facial
Rhytids: Results Across Multiple Clinical Studies. 2006 Summer AAD.

Beddingfield III, Frederick C., MD, PhD; Fagien, Steven, MD; Maas, Corey, MD; Murphy, Diane
K., MBA; Thomas, Jane A., AAS,CCRA; Werschler, W, MD. Juvederm Ultra for Lip
Enhancement: An Open-Label, Multicenter Study. 2009 American Society for Aesthetic
Plastic Surgery.

Schlessinger, J S, Werschler, W P, Kenkel, J. Further Enhancement of Facial Appearance with
a Hydroquinone/Tretinoin Skin Care System in patients previously Treated with Botulinum
Toxin Type A: A Multicenter Investigator-Masked Trial. 2009 ASDS/ASCDAS

Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;
Larsson, T;. Field Treatment With Ingenol Mebutate Gek, 0.015%, 3 Weeks After
Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2012 Winter Clinical
Dermatology Conference Hawaii

Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;
Larsson, T;. Field Treatment With Ingenol Mebutate Gek, 0.015%, 3 Weeks After
Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2013 Maui Derm.

Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;
Larsson, T;. Field Treatment With Ingenol Mebutate Gek, 0.015%, 3 Weeks After
Cryosurgery Of Actinic Keratosis Is Safe And Effective. January 2013 Orlando Dermatology
Aesthetic and Clinical Conference

Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;
Larsson, T;. Field Treatment With Ingenol Mebutate Gek, 0.015%, 3 Weeks After
Cryosurgery Of Actinic Keratosis Is Safe And Effective. April 2013 Dermatology Nurses’
Association 31st Annual Convention

Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Tyring, S; Werschler, W; Knudsen, KM;
Larsson, T;. Field Treatment With Ingenol Mebutate Gek, 0.015%, 3 Weeks After
Cryosurgery Of Actinic Keratosis Is Safe And Effective. May 3013 SOCSS

Werschler, W; Swanson, N; Berman, B;, Goldernberg, G; Hanke, W; Tyring, S; Zografos, P;
Knudsen, KM. Short-term Evaluation of Topical Treatment with Ingenol Mebutate Gel,
0.015%, 3 Weeks after Cryosurgery of Actinic Keratosis on the Face and Scalp. April 2013
South Beach Symposium

Werschler, W; Swanson, N; Berman, B;, Goldernberg, G; Hanke, W; Tyring, S; Zografos, P;
Knudsen, KM. Short-term Evaluation of Topical Treatment with Ingenol Mebutate Gel,
0.015%, 3 Weeks after Cryosurgery of Actinic Keratosis on the Face and Scalp. June 2013
Alabama Derm Summer Symposium

Tyring, S; Berman, B; Swanson, N; Goldenberg, G; Hanke, W; Werschler, W; Zografos, P;
Knudsen, KM. Safety and efficacy of field treatment with ingenol mebutate gel after
cryosurgery for actinic keratosis: comparison with phase 3 results for ingenol mebutate
monotherapy. Accepted presented 2014 Summer AAD.

E-Poster Presentation, AAD, March 21 2015, “Translational Technology for Non-Disruptive
Stratum Corneum High Molecular Weight Carrier Assist”, NuvesseMD, William Werschler,
Dennis Condon, David Richards, Kimberly Duval.
Interviews & Feature Articles

Gillette, Bill. Know In-Office Retailing Pros, Cons. Dermatology Times, February 2005; Vol
26(2).

Gillette, Bill. Maximize Revenue: Work Smart, Not Harder. Dermatology Times, March
2005; Vol 26(3): 78, 82.

Jesitus, John. Innovations address total facial rejuvenation. Dermatology Times, September
2005; Vol 26 (9): 64.

Jesitus, John. Innovations address total facial rejuvenation. Cosmetic Surgery Times,
October 2005; Vol 8(9): 10, 17.

Aesthetics Buyers Guide. OrthoNeutrogena’s Biafine Promotes Cosmetic Wound Healing.
Clinical Roundtable Supplement, January/February 2006; Vol 9(1): 1-8.

Questions and Answers: ASCDAS 4th Annual Meeting. Cosmetic Dermatology, May 2006;
Vol 19(5): 337-338.

Gillette, Bill. U.S. Fillers Market Set To Boom, National Report. Dermatology Times,
September 2006 Vol 27(9); Cover/48-49.

Cosmetic Dermatology Announcement “New Associate Editor-in-Chief”. Cosmetic
Dermatology, September, 2006

Bates, Betsy. Establish Boundaries With Cosmetics Patients. Skin & Allergy News, October
2006; Vol 37(10): 24

Hilton, Lisette. Cosmetic injectables expert finds balance between practice, teaching and
family. Physician Profile, Dermatology Times, October 2006; Vol 27 (10): 138-139

Gillette, Bill. Anti-Aging; ‘Manage’ aging with combinations. Dermatology Times, January
2007; 1/78

American Society of Cosmetic Dermatology & Aesthetic Surgery Presents ASCDAS Physician
Profile. Physician Profile, Cosmetic Dermatology, March 2007; Vol 20(3): 183-184

Gillette, Bill. Derms: The Top Pick AAD print ads aim to position specialty as go-to experts
for anything skin. Dermatology Times, April 2007

Physician Roundtable. Pulsating Clean – Clarisonic brush enhances treatment results.
Healthy Aging, May/June 2007

Kirn, Timothy. Fillers Changing Cosmetic Approach. Skin & Allergy News, January 2008;
Vol 39(1): 19

Jesitus, John. Combining Therapies – Offering the best treatment. Dermatology Times,
February 2008; cover/60/62

Integrating Dermatology and Cosmetic Dermatology Practice: An Expert Interview with
William Philip Werschler, MD. Expert Viewpoint, Medscape Dermatology, November 2008

American Society for Dermatologic Surgery 2008 Annual Meeting. Reshaping the Aging Face
-Video discussion/Conference Coverage, Medscape Dermatology, November 2008

Lowry, Fran. Safety, Efficacy Better With Higher-Dose Hyaluronic Acid Gel Filler. Health
News Daily, December 2008; Vol 20(244)

Lowry, Fran. Higher Dose Improves Filler’s Safety, Efficacy. Aesthetic Dermatology, January
2009; 21

Spencer, Kate. Phil Werschler, MD; Working on a national playing field while living in
Spokane offers this gifted physician – and his patients – the best of both worlds. Smoke
Signals, January 2009, Member Spotlight: 6-7

Ault, Alicia. ASDS, ASCDAS Announce 2009 Joint Meeting. Skin & Allergy News, February
2009, Vol 40(2): 8

SkinMedica, Vogue Interview Taiwan, September 20, 2009.

Werschler, WP. “NouriCel-MD, key to rejuvenation” Vogue-Taiwan, October 2009;
Promotion, 263

Kristin M. Richardson, Scientific Director, MedscapeCME. Werschler, WP. “Disease and
Desire”: Balancing the Therapeutic and Aesthetic Needs of Patients. MedscapeCME
Dermatology. Posted: 11/24/2009

Best Doctors List 2010. Spokane Coeur d’Alene Living, March 2010; Vol 12(2):68

Repinski, Karyn. “Prevention 3rd Annual Defy-Your-Age Beauty Awards” Prevention
Magazine, October 2010; Vol 62(10):106-113

Kevin A. Wilson, Contributing Editor. “Experts Discuss the Art of Neuromodulator
Injections” The Aesthetic Guide, November/December 2010; 34-40

Jane L. Schwanke, “AKs: What are the newest treatments for AKs?” Dermatology Times
special report, May 2011

Lisa B. Samalonis “Cosmetic competition” Dermatology Times, July 2011; Vol 32(7):42-50”

The Wall Street Journal – RE: Verisante Technology, Inc. Welcome onto Clinical Advisory
Board, Tuesday, July 29th, 2014, 10:05 a.m. ET

“Facing the Future” – “Future Faces”, INHealth, supplement to the Inlander, OctoberNovember 2014, Spokane WA.

“Brachytherapy Breakthrough: A new option for treating skin cancer skips the scalpel”,
Inlander, December 1st 2014, Spokane WA

“Embracing Aesthetics” by Laura Beliz, MedEsthetics Magazine, Volume 11, Number 3, April
2015, Featured Article & Cover
Lectures, Presentations & Trainings

Potential Profit Centers to Expand Your Cosmetic Practice, New Opportunities: ‘Private
Label.’ Orlando Dermatology & Aesthetic Conference. January 2006.

Marketing Your Practice. Orlando Dermatology & Aesthetic Conference. January 2006.

Mastering the Art of Soft Tissue Fillers. Orlando Dermatology & Aesthetic Conference.
January 2006.

The Art & Science of Sculptra, Interactive Roundtable Discussion Group. Orlando
Dermatology & Aesthetic Conference. January 2006.

Trainer, Sculptra In-Office Training & Dinner Presentations/Phoenix. January 2006.

Faculty Member, 3rd Annual National Education Faculty Consultant Meeting. Botox
Cosmetic, MedAccess. January 2006.

Non-surgical Total Facial Restoration. National Educators Faculty. January 2006.

Update on Poly-L-Lactic Acid. Hawaii Dermatology Seminar. February 2006.

New Ideas in Wound Healing – Complete Acne Treatment. Hawaii Dermatology Seminar.
February 2006.

Fillers & Faces. Advances in Cosmetic & Medical Dermatology/Hawaii. February 2006.

Botulinum Toxin A & Fillers Live Demonstration. Advances in Cosmetic & Medical
Dermatology/Hawaii. February 2006.

Live Fillers Demonstration. Advances in Cosmetic & Medical Dermatology/Hawaii.
February 2006.

Point: Counterpoint Imiquimod vs. 5- Flurouracil in the Treatment of Actinic Keratoses.
Advances in Cosmetic & Medical Dermatology/ Hawaii. February 2006.

Effudex Teleconference Speaker. Valeant Pharmaceuticals International and StrataMed, a
division of Access Communications Incorporated. February 2006.

Intermediate Cosmetic Surgery Course. American Academy of Dermatology Annual
Meeting/San Francisco. March 2006.

Transitioning a Practice towards Cosmetic Dermatology. American Academy of
Dermatology Annual Meeting/San Francisco. March 2006.

The State of the Art of Aesthetic Dermatology. Live Patient Demonstrations. American
Academy of Dermatology Annual Meeting/San Francisco. March 2006.

Botox for the Upper Face: Anatomy and Treatment Considerations. Allergan Aesthetic
Conference/Madrid, Spain. April 2006.

Update on Clinical Research of Botulinum Toxins. Allergan Aesthetic Conference/ Madrid,
Spain. April 2006.

Trainer, Sculptra In-Office Training & Dinner Presentations/New York. April 2006.

Advisor, Facial Aesthetics Advisory Board Meeting. Allergan, and Inamed, a division of
Allergan. April 2006.

Update in Cosmetic Dermatology. Presentation hosted by Clarisonic, a division of Pacific
Bioscience Laboratory, Inc/Seattle. June 2006.

A New Look, Innovations in Facial Assessment & Evaluation of Treatment Options. Jointly
sponsored by Dannemiller Memorial Educational Foundation and SCIOS Continuing
Education. Supported by Dermik Laboratories, a business of Sanofi-Aventis U.S./Denver.
July 2006.

Lecture: Optimizing Treatment Outcomes – Toxin & Filler. Pacific Northwest
Dermatological 73rd Annual Scientific Conference, Portland Oregon. July 2006

Faculty. Botulinum Toxin and Fillers: An Interactive, Experiential Session. American
Academy of Dermatology, San Diego, CA. July 2006

Trainer Sculptra, Advance Injection Technoligies, Scottsdale, Arizona, September 2006

Trainer Sculptra, Advance Injection Technoligies, Las Vegas, Nevada, September 2006

Trainer Sculptra, Advance Injection Techniques, San Diego, California, September 2006

Trainer, Allergan, Aesthetic Managers Meeting; “Live demonstration of Juvederm Injection
Techniques, and update on Facial Fillers.” Anaheim, California, September 2006.

Featured Lecturer, For the Core by the Core; “Sculptra Update; Radiesse Review; Overview
of the US Filler, Toxin and Aesthetic Marketplace.” San Francisco, CA, September 2006

Guest Lecturer, International Society of Cosmetic and Laser Surgeons, “The Art of the
Effective Patient Consultation” Annual Meeting, Las Vegas, NV, September, 2006

Invited Injection Technique Instructor, Allergan National Education Faculty Meeting, Special
Edition (Juvederm Launch), Laguna Beach, CA, September, 2006

Program Conference Chair, “Advanced Aesthetic Injection Techniques”, MedAccess, Des
Moines, IA, October, 2006

Trainer, Dermik Aesthetics, “Advanced Injection Techniques for Pan-Facial Sculpting” NYC,
NY, October, 2006

Late Breaking Abstracts, “PLLA (Sculptra) Cosmetic Clinical Trial Data: Efficacy of Injectable
Poly-L-lactic Acid versus Human Collagen for the Correction of Nasolabial Fold Wrinkles”
Palm Springs, CA, ASDS Annual Meeting, October, 2006

All About Botox, “Treatment of the Periocular Area and Practice Pearls”, Palm Springs, CA,
ASDS Annual Meeting, October, 2006

Invited Guest Lecturer, Dermik Aesthetics, “Advanced Injection Techniques for Pan-Facial
Sculpting”, Palm Springs, CA, October, 2006

Faculty. Allergan Aesthetic Conference. Madrid, April 2006

Clinical Reflections on Facial Aging: The Foundation for Renewal. Regional workshop series
and symposium. Advances in Cosmetic and Medical Dermatology, January 2007

Faculty. Dermik Steering Committee Meeting. Washington D.C., February 2007

Faculty. American Academy of Dermatology 65th Annual Meeting. Washington D.C.,
February 2007

Facial Aging: Review of Current Treatment Options, Patient Assessment, and Combination
Usage. Advances in Cosmetic and Medical Dermatology, Hawaii, 2007

Lecture: New Approaches to Fillers and Botulinum Toxin. ISCLS 16th International
Symposium on Cosmetic Laser Surgery. Las Vegas, Nevada, September, 2007

Faculty. Facial Aesthetic Advisory Board Meeting. Dermik. New York, November 2007

Faculty. Juvederm Volumizing Advisory Board. Dallas, Texas, November, 2007

Symposium Faculty. New Vistas in Facial Aesthetics. 31st Annual Hawaii Dermatology
Seminar. Wailea, Maui, Hawaii, March 2008

Faculty. Clinical Reflections on Facial Aging: The Foundation for Renewal. Regional
workshop series and symposium. Las Vegas, NV, April 2007

Faculty. Medical Aesthetics – The Art of Skin Rejuvenation; Pharmaceutical / Topical
Options. The Aesthetic Show CME Scientific Program. Las Vegas, NV, May 2007.

Program Director. The Aesthetic Show Scientific Program. Las Vegas, NV, June 2009

Trainer/Lecture: Facial Shape and Volume – Addressing Deflationary Issues. 33rd Annual
Hawaii Dermatology Seminar. Hawaii, February 2009

Faculty. AACS 27th Annual Meeting. Phoenix, AZ Jan, 2011

Faculty. AAD New Orleans February, 2011

Faculty. Leo Pharma Advisory Board. Hawk Partners – Derm perspective on Physiciandispensed treatment discussion. Maui Derm, Hawaii February, 2011

Faculty. ASCDAS. Santa Monica, CA March, 2011

Faculty. ASDF Hawaii Derm. March, 2011

Faculty. Merz Aesthetics Radiesse Injection Training (The Aesthetic Academy) Los Angeles,
CA April, 2011

Trainer. Scientiae, Seattle, Washington. PALETTE workshop May, 2011

Faculty. The Aesthetic Show. Las Vegas, NV 2011

Multi-specialty Meeting, Las Vegas, NV 2011

Paradigm Medical. Faculty and Presentation. “Noninvasive Injectables in Facial Aesthetic
Therapy”. Denver, CO 2011

Faculty. Oregon Dermatology Society Annual Summer Meeting. Sunriver, OR

Advisory Board, LaViv-BioCentric. New York, 2011

Injector Trainer, Paradigm Medical. Seattle, WA 2011

Merz Aesthetics European Expert Summit. Merz Aesthetics, Berlin 2011

Trainer, Interactive workshops/Neurotoxins and Fillers. ASCDAS, Las Vegas 2011

Merz Educational Grant, Paradigm Curriculum Development. Miami Beach, FL January,
2012

Instructor, American Academy of Cosmetic Surgery, Las Vegas, January, 2012

Faculty. 8th Annual Maui Derm. Maui, HI February, 2012

Advisory Board, XODIAK Ad Board Meeting Merz Aesthetics. Dallas, TX February 2012

Faculty. The Aesthetic Show. Las Vegas, NV April, 2012.

Faculty. Multi-Specialty Meeting. Las Vegas, NV June, 2012

Faculty. PALETTE Injection course and cannula Technique Presentation. Scientiae. Seattle,
WA August, 2012

Advisory Board Meeting. Galderma Erythema Regional Advisory Board Meeting.
Washington, DC October, 2012

Presentation, “Radiessse Volumizing Filler” MAEXS Meeting, Merz Aesthetics Amsterdam.
November 2012

Faculty/Moderator and Live Surgery Demonstration. AACS Las Vegas, NV January, 2013

Faculty. Presentation “Fillers by Region”, “Neurotoxin and Dermal Filler Workshop”.
MauiDerm, Maui, HI February, 2013

Faculty. Scientiae PALETTE Meeting. Palo Alto, CA February, 2013

Trainer. Scientiae PALETTE Program. Seattle, WA March, 2013

Faculty. Scientiae PALETTE Program. Washington, DC April 2013

Presentation. Paradigm Medical, “Innovations in Facial Aesthetic Medicine. Seattle, WA
April, 2013

Investigator Meeting. Suneva Medical, Suneva acne scar study. Los Angeles, CA April, 2013

Faculty, presentation. The Aesthetic Show, “Advanced Neuromodulator Techniques” and
“Advanced Dermal Filler Techniques.” Las Vegas, NV May, 2013

Presentation. Paradigm Medical, “Innovations in Facial Aesthetic Medicine. Denver, CO.
June, 2013

Faculty. Advisory Board. Lectures. ACMD, Maui, HI June, 2013

Presentation. Paradigm Medical. Live Injections. Scottsdale, AZ July 2013

Trainer. Galderma. Brimonidine (Rosacea). Dallas, TX August 2013

Trainer. Scientiae PALLETTE Program. Seattle, WA September 2013

Presentation. Paradigm Medical. Live Injections. Vancouver, WA October 2013

Investigator Meeting. Site Solutions Summit, Amelia Island, FL October 2013

Advisory Board Meeting, Voluma, Los Angeles, CA October 2013

Data Safety Monitoring Board, Ulthera, October/November 2013

Advisory Board Meeting, Merz Partners, Atlanta, GA November 2013

Aesthetic Expert Summit, Paris, France, November 2013

Advisory Board Meeting, PolyRemedy, Palo Alto, CA December 2013

Investigator Meeting, Aczone, Dallas, TX December 2013

Faculty. Live Surgery Demonstration, Moderator, Injector. American Academy of Cosmetic
Surgery, Las Vegas, NV January 2014

Faculty. Presentation “Toxin and Filler Update”, “Neuromodulator and Dermal Filler
Workshop”. MauiDerm, Maui, HI January, 2014

Advisory Board Meeting. Galderma, Maui, HI January 2014

Advisory Board Meeting, TaroPharma, Maui, HI January 2014

Advisory Board Meeting, Promius Pharma, Maui, HI January 2014

Faculty. The Aesthetics Academy, San Francisco, CA February 2014

Presentation. Paradigm Medical. Live Injections. San Francisco CA February 2014

Faculty. American Academy of Dermatology, Denver CO March 2014

Advisory Board Meeting. Merz, Denver CO March 2014

Advisory Board Meeting, ARTAS, Denver CO March 2014

Advisory Board Meeting, Sente, Denver CO, March 2014

Speaker Program. Advanced Rad Solutions, Seattle WA March 2014

Presentation. Paradigm Medical. Live Injections. Chicago IL April 2014

Advisory Board. Allergan, Hollywood, CA April 2014

Presentation. Paradigm Medical. Live Injections. Scottsdale, AZ April 2014

Advisory Board Meeting. Nuvesse Skin Therapies, San Francisco CA April 2014

Presentation. Paradigm Medical. Live Injections. Seattle, WA May 2014

Presentation. Paradigm Medical. Live Injections. Denver, CO May 2014

Advisory Board Meeting. PolyRemedy, San Francisco, May 2014

Investigator Meeting. Suneva, Chicago IL May 2014

Investigator Meeting. Galderma, Dallas TX May 2014

Presentation. Paradigm Medical. Live Injections. Denver, CO May 2014

Investigator Meeting. Suneva, Las Vegas June 2014

Faculty. Multi-Specialty Meeting, Las Vegas NV June 2014

Advisory Board Meeting. Nuvesse Skin Therapies, Las Vegas NV June 2014

Presentation. Ulthera, Las Vegas NV June 2014

Presentation. Paradigm Medical. Live Injections. Park City UT June 2014

Faculty. NP+PA MauiDerm, Park City UT June 2014

Faculty. The Aesthetics Show, Las Vegas, NV July 2014

Advisory Board Meeting. Nuvesse Skin Therapies, Las Vegas NV July 2014

Advisory Board Meeting. Merz, Las Vegas NV July 2014

Advisory Board Meeting. Ulthera, Las Vegas NV July 2014

Presentation. Pacific Northwest Dermatology, Seattle WA July 2014

Advisory Board and Filming, Suneva Los Angeles CA July 2014

Advisory Board Meeting. Belotero, San Francisco July 2014

Advisory Board Meeting. Suneva Injection Training Workshop Filming for Acne Scars,
August 2014

Advisory Board Meeting. Suneva Board Presentation, Los Angeles, CA August 2014

Advisory Board Meeting, Belotero, Dallas, TX August 2014

Trainer. Scientiae PALLETTE Program. Seattle, WA September 2014

Advisory Board Meeting. Belotero, Portland OR September 2014

Advisory Board Meeting. Nuvesse, Castro Valley, CA September 2014

Advisory Board Meeting. Voluma Virtual, September 2014

Advisory Board Meeting. Restylane Silk, Galderma. Montreal, October 2014

Educational Speaker. Celgene. Portland, OR October 2014

CME Initiative Program. Paradigm. Chicago, IL November 2014

Advisory Board Meeting. Belotero. Oak Brook, IL November 2014

Advisory Board Meeting. IcadMed. San Diego, CA November 2014

Ulthera Presentation at ASDS. Ulthera. San Diego, CA November 2014

Educational Webinar. Paradigm. Scottsdale, AZ November 2014

Palette Workshop. Scientiae. Seattle, WA November 2014

THE Aesthetic Academy Presentation. THE Aesthetic Academy. Washington DC, November
2014

Ulthera Presentation. THE Aesthetic Academy. Washington DC, November 2014

Expert Meeting. Belotero. Bellevue, WA December 2014

Merz NA Partners meeting. Orlando, FL December 2014

Galderma Injector Training. Dallas, TX January 2015

AACS 2015. Master Session: Facial Resurfacing and Skin Tightening: Micro-Focused
Ultrasound. New Orleans, LA January 2015

AACS 2015. Ultherapy Presentation: Micro-focused Ultrasound with Visualization (MFU-V)
for Lifting and Tightening of Facial and Neck Skin Laxity Using a High-Density, Vectoring
approach, during Session: Free paper Session on Brow, Blepharoplasty, Otoplasty and
Facial Skin Tightening. New Orleans, LA January 2015

AACS 2015. Ultherapy Presentation: Micro-focused Ultrasound with Visualization (MFU-V)
for New and Exciting Uses. New Orleans, LA January 2015

Advisory Board Meeting. MauiDerm. Maui, HI. January 2015

MauiDerm 2015. Faculty: “Toxins: Onstage Live Patient Demonstration”. Maui, HI.
January 2015

MauiDerm 2015. Faculty: “Lunch with the Faculty: Onstage Live Patient Demonstration”.
Maui, HI. January 2015

MauiDerm 2015. Faculty: “Neuromodulator and Dermal Filler Injection Workshops-Small
Group Breakout Sessions”. Maui, HI. January 2015

Advisory Board Meeting. Sculptra. Scottsdale, AZ. February 2015

Advisory Board Meeting. Neothetics. Miami Beach, FL. February 2015

AbbVie Speaker Program. Humira. Bellevue, WA. John Howie Steakhouse. February 2015

AbbVie Speaker Program. Humira. Anchorage, Ak. Fortson Dermatology & Skincare
February 2015

AbbVie Speaker Program. Humira. Anchoarge, Ak. Glacier Brewhouse. February 2015

AbbVie Speaker Program. Humira. Anchorage, Ak. Alaska Center for Dermatology.
February 2015

Bellafill Acne Scar Training. Suneva. Las Vegas, NV. Four Seasons Hotel. February 2015

Faculty. Paradigm. Facial Aesthetics: Advanced Techniques for Full Face Rejuvenation.
Hyatt Regency Bellevue. Bellevue, WA. March 2015

Faculty. Paradigm. Facial Aesthetics: Advanced Techniques for Full Face Rejuvenation.
The Ritz-Carlton Denver. Denver, CO. March 2015

Advisory Board Meeting. Dermira. AAD 2015. San Francisco, CA. March 2015

Advisory Board Meeting. Xoft. AAD 2015. San Francisco, CA. March 2015

Investigator Meeting. B.I. AAD 2015. San Francisco, CA. March 2015

Faculty. AAD. Course C007: Avoiding and Managing Filler Complications. AAD 2015. San
Francisco, CA. March 2015

Editorial Board Meeting. SKINmed. AAD 2015. San Francisco, CA. March 2015

Faculty Meeting. Association of Surgical Faculty. AAD 2015. San Francisco, CA. March
2015

AbbVie Speaker Program. Humira. Kennewick, WA. Cedars Restaurant. March 2015